New Drugs in Oncology: Benefits, Risks and Challenges

被引：2

|

作者：

Cella, David ^{[1
]}

Vervoelgyi, Volker ^{[2
]}

Woermann, Bernhard ^{[3
]}

机构：

[1] Northwestern Univ, Dept Med Social Sci, Chicago, IL 60611 USA

[2] Inst Qual & Wirtschaftlichkeit Gesundheitswesen I, Cologne, Germany

[3] Deutsch Gesell Hamatol & Med Onkol DGHO, Berlin, Germany

来源：

ONKOLOGIE | 2013年 / 36卷

关键词：

PATIENT-REPORTED OUTCOMES; PROGRESSION-FREE SURVIVAL; QUALITY-OF-LIFE; FUNCTIONAL ASSESSMENT; CANCER-THERAPY; LUNG-CANCER; END-POINT; RCC;

D O I：

10.1159/000352000

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

收藏

页码：12 / 19

页数：8

相关论文

共 50 条

[41] Two New Drugs for Homozygous Familial Hypercholesterolemia Managing Benefits and Risks in a Rare Disorder
Smith, Robert J.
JAMA INTERNAL MEDICINE, 2013, 173 (16) : 1491 - 1492
[42] Payers' Management of Oncology Drugs: Opportunities and Challenges
Kenney, James T., Jr.
AMERICAN HEALTH AND DRUG BENEFITS, 2014, 7 (03): : 123 - 124
[43] Challenges in Expediting the Development of Oncology Drugs Reply
Hwang, Thomas J.
JCO ONCOLOGY PRACTICE, 2023, 19 (04) : 217 - +
[44] Special challenges in the outsourced manufacture of oncology drugs
Kaufman, Michael J.
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2010, 240
[45] Powerful medicines: The benefits, risks, and costs of prescription drugs
Lipton, H
HEALTH AFFAIRS, 2005, 24 (04) : 1172 - 1173
[46] RISKS AND BENEFITS OF DRUGS USED IN THE MANAGEMENT AND PREVENTION OF GOUT
CONAGHAN, PG
DAY, RO
DRUG SAFETY, 1994, 11 (04) : 252 - 258
[47] Pharmacoepidemiology - Assessing the risks and benefits of drugs in the postmarketing phase
Meier, CR
CHIMIA, 2006, 60 (1-2) : 54 - 57
[48] Powerful medicines - The benefits, risks, and costs of prescription drugs
Kessler, DP
SCIENCE, 2004, 306 (5705) : 2192 - 2193
[49] Benefits of labour-stimulating drugs outweigh risks
Reactions Weekly, 2016, 1583 (1) : 2 - 2
[50] Glucose-lowering drugs: balancing risks and benefits
不详
LANCET DIABETES & ENDOCRINOLOGY, 2017, 5 (09): : 669 - 669

← 1 2 3 4 5 →